Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program [megakaryocyte RNA-seq]

ABSTRACT: Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program

ORGANISM(S): Mus musculus

PROVIDER: GSE299806 | GEO | 2026/09/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program [CUT&RUN]

Project description:Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program

2026-09-18 | GSE299814 | GEO

Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program [Patient scRNA-seq]

Project description:Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program

2026-09-18 | GSE299819 | GEO

Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program [murine scRNA-seq]

Project description:Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program

2026-09-18 | GSE299817 | GEO

Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program

Project description:Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program

| PRJNA1276564 | ENA

Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program [megakaryocyte RNA-seq]

Project description:Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program [megakaryocyte RNA-seq]

| PRJNA1276552 | ENA

Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program [CUT&RUN]

Project description:Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program [CUT&RUN]

| PRJNA1276572 | ENA

Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program [Patient scRNA-seq]

Project description:Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program [Patient scRNA-seq]

| PRJNA1276573 | ENA

Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program [murine scRNA-seq]

Project description:Mutant ASXL1 exacerbates CALR-mutant MPN by enhancing a distinct megakaryocyte differentiation program [murine scRNA-seq]

| PRJNA1276574 | ENA

Whole-genome CRISPR screening identifies N-glycosylation as an essential pathway and a potential novel therapeutic target in CALR-mutant MPN (Pooled CRISPR Screen).

Project description:Calreticulin (CALR) mutations are frequent, disease-initiating events in myeloproliferative neoplasms (MPN). Although the biological mechanism by which CALR mutations cause MPN has been elucidated, there currently are no clonally selective therapies for CALR-mutant MPN. To identify unique genetic dependencies in CALR-mutant MPN, we performed a whole-genome CRISPR knockout depletion screen in mutant CALR-transformed hematopoietic cells. We found that genes in the N-glycosylation pathway (amongst others) were differentially depleted in mutant CALR-transformed cells as compared with control cells. Using a focused pharmacological screen targeting unique vulnerabilities uncovered in the CRISPR screen, we found that chemical inhibition of N-glycosylation impaired the growth of mutant CALR-transformed cells in vitro. We treated Calr-mutant knockin mice with the N-glycosylation inhibitor, 2-deoxy-glucose (2-DG), and found a preferential sensitivity of Calr-mutant cells to 2-DG as compared to wild-type cells, and a normalization of key MPN disease features. These findings advance the development of clonally selective treatments for CALR-mutant MPN.

2022-09-21 | GSE203455 | GEO

Whole-genome CRISPR screening identifies N-glycosylation as an essential pathway and a potential novel therapeutic target in CALR-mutant MPN (Whole Genome CRISPR Screen).

2022-09-21 | GSE203456 | GEO